PrecisionLife has partnered with healthcare center the Metrodora Institute to jumpstart the diagnosis and treatment options for a range of chronic diseases including long COVID, ME/CFS, ALS and Sjögren's syndrome.
TILT Biotherapeutics, a clinical-stage biotech company developing cancer immunotherapies, has received a $2 million grant from the U.S. Department of Defense (DOD) for a three-year project to treat ovarian cancer using its TILT-123 asset.
The US FDA has granted fast track designation to CAN-3110, a viral immunotherapy candidate from Candel Therapeutics to treat patients with recurrent high-grade glioma (HGG) and improve overall survival.
Stella Vnook, a seasoned veteran in the pharmaceutical industry with extensive experience in senior leadership roles at Catalent, Merck, and Diverse Biotech, has been a prominent figure in the field, particularly in oncology, for over 25 years.
Following positive advice from the Scottish Medicines Consortium (SMC), the first biologic treatment for inflammatory skin disease, hidradenitis suppurativa (HS), is now available in Scotland on the NHS.
Japanese pharmaceutical company Shionogi has announced the first peer-reviewed publication of its phase 3 study investigating ensitrelvir to treat patients with mild to moderate COVID-19 in Japan, South Korea and Vietnam.
Alys Pharmaceuticals, an immuno-dermatology focused company, has launched with $100 million financing by Medicxi and an R&D pipeline enabled by multiple platform technologies.
Sano Chemicals has begun its phase 1, first-in-human clinical trial of Occidiofungin, a new treatment to cure recurrent vaginal yeast infections or vulvovaginal candidiasis (RVVC).
GSK’s vaccine Arexvy is currently undergoing regulatory review with the potential of being approved in Europe for use in adults aged between 50 and 59 who are at an increased risk for respiratory syncytial virus (RSV) infection.
Outsourcing Pharma and BioPharma Reporter breaks down the key people on the move in the pharma industry. Enhanc3D Genomics, Cytomos and Cellular Origins are among the companies welcoming new faces to top jobs.
A collaboration to expand autologous CAR-T programs into trials for multiple cancers in a cost-efficient way, has been formed by BioNTech SE and Autolus Therapeutics plc.
Rani Therapeutics, a clinical-stage biotherapeutics company focused on the oral delivery of biologics, has announced encouraging results from its phase 1 study of RT-111, a RaniPill capsule containing an ustekinumab biosimilar, CT-P43.
Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, has completed a pre-investigational new drug (pre-IND) meeting with the FDA for a phase 1/2 clinical trial of its cell therapy product, CTH-401 for the treatment...
AbbVie has announced that the National Institute for Health and Care Excellence (NICE) has recommended epcoritamab (tepkinly), its treatment for adults with diffuse large B-cell lymphoma (DLBCL), an aggressive and fast-growing blood cancer, whose cancer...
Upon hearing the phrase ‘cancer treatment’, the first word that can typically spring to mind is chemotherapy – a primary therapy which uses powerful chemicals to destroy rapidly growing cancer cells in the body.
Synthetic biology company Asimov has launched its new LV edge packaging system, which it claims will improve the cost efficiency and reduce the supply chain risk of lentiviral production.
Biotechnology company Vergent Bioscience has revealed that VGT-309, its investigational tumor-targeted fluorescent imaging agent, is able to help surgeons see lung tumors in real time during surgical procedures.
Colleen Acosta is CEO of Freya Biosciences which is a trans-Atlantic clinical-stage biotech company pioneering microbial immunotherapies aimed at relieving the chronic inflammation underlying a range of women’s reproductive system conditions and we were...
We sat down with Xiaojun Liu, director of AAV process development at ReciBioPharm, to discuss the growing need for carefully designed platforms to deliver safe and cost-effective AAV therapies to patients at pace.
PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), and the Flow Cytometry Facility at the Babraham Institute have announced a collaboration to develop a bespoke cell phenotyping...
Danish biotech company Vesper Bio has been awarded a grant worth $873,000 by The Michael J. Fox Foundation (MJFF) to assess sortilin inhibition in Parkinson’s disease.
Stimulants, amphetamines, and methylphenidates are currently the first-line treatment for moderate to severe attention-deficit/hyperactivity disorder (ADHD) across the seven major global markets; France, Germany, Italy, Spain, the UK, the US, and Japan....
Abzena, an end-to-end CDMO for biologics and bioconjugates, has launched AbZelect and AbZelectPRO cell line development (CLD) platforms to accelerate cell lie production for manufacturing antibodies and recombinant proteins.
The Cell and Gene Therapy Catapult (CGT Catapult), an independent organization specialising in the advancement of cell and gene therapies, has revealed that the UK has remained an attractive destination for commercial trials, with this type of clinical...
Despite the current Bruton tyrosine kinase (BTK) inhibitor market being valued at approximately $6 billion, sales specifically for chronic lymphocytic leukemia (CLL) are predicted to be nearly $5 billion by 2032 in the seven major markets.
Oncology company Oxford BioTherapeutics has announced that the first patient has been dosed in a phase 1b trial investigating its lead candidate OBT076, in patients with Adenoid Cystic Carcinoma (ACC) of the head and neck.
Tola Olorunnisola is currently senior vice president, clinical services & strategy at Avantor and along with her team is working on delivering digital innovations in the lab.
TrakCel, a provider of cellular orchestration systems to the cell and gene therapy (CGT) industry, has launched its own consultancy services to share its process development knowledge with the broader community of CGT developers.
Abbott and Tandem Diabetes Care recently announced the wireless integration of Abbott’s FreeStyle Libre 2 Plus continuous glucose monitor with the Tandem t:slim X2 insulin pump in the US.
CellVoyant, an AI-first biotechnology spin-out from the University of Bristol accelerating the development of novel cell therapies, has announced a £7.6 million seed round.
Sexual health pharmaceutical company Futura Medical has extended its exclusive licensing agreement with Cooper Consumer Health for the rights to commercialize its topical, gel-based erectile dysfunction treatment.
Following the news that AbbVie has launched Produodopa to treat severe motor fluctuations in patients with advanced Parkinson’s disease (PD) in the European Union (EU), Christine Wong, neurology analyst at GlobalData, offers her view:
Ariceum Therapeutics, a biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, has submitted an application with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to...
Transgene and NEC are planning to extend their randomized phase 1 trial into a phase 2 study in 2024 to further demonstrate the potential of TG4050, a neoantigen vaccine for head and neck cancers.
We caught up with Kevin Knopp, CEO and co-founder of 908 Devices, to discuss the main obstacles in cell and gene therapy manufacturing and how the company's recent partnership with Terumo Blood and Cell Technologies is tackling these challenges.
Merck has announced a new licensing agreement with Inspirna for ompenaclid, a first-in-class treatment currently in phase 2 development for RAS-mutated (RASmut) advanced or metastatic colorectal cancer (mCRC).
Healthcare industry professionals scored cell and gene therapy (CGT) as the industry trend to have the greatest impact on the pharmaceutical industry in 2024, in a recent survey launched by data and analytics firm GlobalData.